^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR8 inhibitor

    Related drugs:
    13d
    A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | N=535 --> 77
    Enrollment closed • Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab)
    1m
    Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Recruiting, Domain Therapeutics Australia Pty Ltd | N=60 --> 125
    Enrollment change • Checkpoint inhibition
    1m
    BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • ABP 206 (nivolumab biosimilar)
    2ms
    A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=129, Active, not recruiting, Bayer | Trial primary completion date: Oct 2026 --> Jul 2026
    Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab)
    2ms
    KEYNOTE-F22: A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=34, Terminated, Zai Lab (Hong Kong), Ltd. | N=60 --> 34 | Trial completion date: Mar 2027 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Aug 2025; Sponsor Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ZL-1218
    2ms
    A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=535, Recruiting, Amgen | Trial completion date: Dec 2028 --> Mar 2028 | Trial primary completion date: Mar 2028 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab)
    2ms
    CITY: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P1 trial • First-in-human
    3ms
    CA052-002: A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=949, Recruiting, Bristol-Myers Squibb | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • docetaxel
    3ms
    A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=129, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | N=354 --> 129
    Enrollment closed • Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab)
    3ms
    CHS-114-102: A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=154, Recruiting, Coherus Oncology, Inc. | N=72 --> 154
    Enrollment change
    |
    cisplatin • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • tagmokitug (CHS-114)
    3ms
    Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=392, Active, not recruiting, LaNova Medicines Limited | Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Dec 2025
    Enrollment closed • Trial primary completion date
    |
    Loqtorzi (toripalimab-tpzi) • cafelkibart (LM-108)
    3ms
    Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=78, Completed, LaNova Australia Pty Limited | Recruiting --> Completed | N=60 --> 78
    Trial completion • Enrollment change • First-in-human
    |
    cafelkibart (LM-108)